RWB
TVRD

RMR Wealth Builders’s Tvardi Therapeutics TVRD Stock Holding History

RMR Wealth Builders’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1
Closed -$1K – 745
2021
Q1 		$1K Hold
1
– – ﹤0.01% 775
2020
Q4 		$0 Buy
+1
New +$524 ﹤0.01% 561
2020
Q3 		– Sell
-1
Closed -$1K – 473
2020
Q2 		$1K Buy
+1
New +$552 ﹤0.01% 433
2019
Q4 		$0 Buy
+1
New +$702 ﹤0.01% 416

Other funds holding TVRD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return

RMR Wealth Builders's TVRD Position: Q2 2021 in Review

RMR Wealth Builders sold out of Tvardi Therapeutics (TVRD) in Q2 2021, closing a stake of 1 share — an estimated $1K sold.

RMR Wealth Builders first reported a position in TVRD in Q4 2019 and held it in 4 quarters. The position peaked at $1K in Q1 2021. 174 funds tracked by Wall St. Rank hold TVRD as of Q2 2021.

  • RMR Wealth Builders reported no remaining Tvardi Therapeutics position as of Q2 2021 after selling out during the quarter.
  • RMR Wealth Builders sold 1 Tvardi Therapeutics share in Q2 2021, an estimated $1K.
  • RMR Wealth Builders first reported a position in Tvardi Therapeutics in Q4 2019 and held it in 4 quarters.
  • RMR Wealth Builders's Tvardi Therapeutics position peaked at $1K in Q1 2021.
  • 174 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2021.

Based on RMR Wealth Builders's 13F filing for Q2 2021, filed 16 Aug 2021.